Process Engineer /Scientist We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment and teamwork, and so can you. OXB’s Manufacturing, Science and Technology Team is responsible for process and technology development activities from early concept through to product registration for market approval, and to ensure that OXB’s new and existing manufacturing processes can deliver the productivity, performance, quality and cost benefits required in line with regulatory guidance. We are currently recruiting for two Process Engineer or Scientists to join the team. One of the main purposes of this role is to plan, execute and report completion of MSAT-related projects or tasks in alignment with department objectives Your responsibilities in this role would be: • Delivering assigned technical projects/tasks working directly with your manager to ensure project timelines are met according to internal and/or customer needs • Trouble shooting, identification and problem solving in the plant for process and quality issues of existing processes • Supporting the implementation of new processes/products into OXB facilities and third party CMOs • Supporting improvement projects to achieve increased productivity improvement, quality and reliability improvements • Analysing batch records and quality results and monitors consistency of operations by using appropriate database and statistical tools; propose and implement corrective and improvement actions • Working will be conducted in compliance with OXB’s Quality, Safety and Environmental systems and procedures We are looking for: • Relevant degree or equivalent experience • Knowledge of GMP manufacturing, including quality and regulatory requirements • Knowledge and relevant experience in the scale up and commercialisation of GMP manufacturing bioprocesses • Understanding of quality management systems, environmental, health and safety aspects of the work and regulatory requirements • Experience of using statistical data analysis tools • Understanding of Process Hazard Analysis (PHA) methodologies such as FMEA, HAZOP and HACCP would be desirable About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • Our values are: Responsible, Responsive, Resilient, Respect • State of the art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you. Collaborate. Contribute. Change lives Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.